What medications are recommended for treating symptomatic hypotension, including orthostatic and neurogenic types?

Medications for Hypotension

For symptomatic neurogenic orthostatic hypotension, midodrine and droxidopa are the first-line pharmacological agents, with midodrine being the only FDA-approved medication specifically for this indication. 1

Initial Approach: Non-Pharmacological Measures First

Before initiating medications, the following steps are essential:

• Eliminate offending medications (diuretics, vasodilators, psychotropic drugs, α-adrenoreceptor antagonists) as drug-induced hypotension is the most common reversible cause 1
• Correct volume depletion through fluid resuscitation (oral or intravenous) in acute dehydration 1
• Implement physical countermeasures: leg crossing, squatting, lower body muscle tensing increase blood pressure through isometric contraction 1
• Apply compression garments (at least thigh-high, preferably including abdomen) to improve orthostatic symptoms 1
• Acute water ingestion (≥240-480 mL) provides temporary relief with peak effect at 30 minutes in neurogenic orthostatic hypotension 1

First-Line Pharmacological Agents

Midodrine (Strongest Recommendation)

Midodrine is the primary first-line medication with Class I recommendation for symptomatic orthostatic hypotension. 1

• Mechanism: Peripheral selective α1-adrenergic agonist causing arteriolar and venous constriction 1
• Dosing: Individually titrated up to 10 mg two to four times daily, with first dose before arising 1
• Efficacy: Dose-dependent blood pressure increase with symptom improvement 1
• Key adverse effects: Supine hypertension (major limiting factor), scalp tingling, piloerection, urinary retention, bradycardia 1
• Critical caveat: Avoid several hours before planned recumbency, especially with documented supine hypertension 1

Droxidopa (Strong Alternative)

Droxidopa is equally effective as midodrine for neurogenic orthostatic hypotension with Class IIa recommendation. 1

• Mechanism: Norepinephrine precursor effective in Parkinson disease, pure autonomic failure, and multiple system atrophy 1
• Additional benefit: May reduce falls according to small studies 1
• Important interaction: Carbidopa in Parkinson patients may decrease droxidopa effectiveness 1
• Adverse effects: Supine hypertension, headache, dizziness, nausea 1

Second-Line Pharmacological Options

Fludrocortisone

Fludrocortisone can be beneficial but should be used after midodrine/droxidopa due to concerning long-term effects. 1

• Mechanism: Increases plasma volume through sodium retention, direct vessel constriction, and reduced vessel wall distensibility 1
• Dosing: Start 0.05-0.1 mg daily, titrate to 0.1-0.3 mg daily 1
• Major concern: When supine hypertension is present, other medications should be used before fludrocortisone 1
• Serious adverse effects: Adrenal suppression and immunosuppression with doses >0.3 mg daily, plus edema, hypokalemia, congestive heart failure 1

Salt and Fluid Supplementation

Increased salt (6-9 g or 1-2 teaspoons daily) and fluid intake may be reasonable in selected patients without contraindications. 1

• Contraindications: History of hypertension, renal disease, heart failure, or cardiac dysfunction 1
• Limited benefit: In patients with already high salt intake 1

Refractory Cases: Additional Agents

Pyridostigmine

For patients refractory to first-line agents, pyridostigmine may be beneficial (Class IIb). 1

• Mechanism: Improves orthostatic tolerance through increased peripheral vascular resistance 1
• Adverse effects: Nausea, vomiting, abdominal cramping, sweating, salivation, urinary incontinence 1

Octreotide

Octreotide may be beneficial specifically for refractory postprandial or neurogenic orthostatic hypotension. 1

• Mechanism: Reduces splanchnic blood flow by ~20%, preventing postprandial hypotension 1
• Specific indication: Splanchnic circulation pooling that worsens postprandially 1

Special Considerations for Neurogenic vs. Non-Neurogenic

The distinction between neurogenic and non-neurogenic orthostatic hypotension has critical therapeutic implications:

• Neurogenic (peripheral denervation): Responds better to norepinephrine agonists/precursors like droxidopa and midodrine 2
• Central autonomic dysfunction: Responds better to norepinephrine reuptake inhibitors like atomoxetine 2, 3

Critical Management Principle

The therapeutic goal is minimizing postural symptoms and improving quality of life, NOT normalizing blood pressure. 1

The major treatment challenge is balancing standing blood pressure improvement against avoiding marked supine hypertension. 1

Common Pitfalls to Avoid

• Do not use fludrocortisone as first-line when supine hypertension is present 1
• Do not administer midodrine before planned recumbency due to supine hypertension risk 1
• Do not add salt/fluid in patients with hypertension, renal disease, or heart failure 1
• Do not overlook medication review as the most common reversible cause 1